Literature DB >> 22168373

Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Enrique R Pouget1, Holly Hagan, Don C Des Jarlais.   

Abstract

AIMS: We conducted a systematic review of studies reporting seroincidence of hepatitis C infection (HCV) in relation to shared syringes and drug preparation equipment among injection drug users (IDUs). We identified published and unpublished studies that met inclusion criteria.
DESIGN: We estimated the relative contributions of shared syringes and drug preparation equipment to HCV transmission using random-effects meta-analysis, and analyzed potential sources of heterogeneity of effects among studies.
FINDINGS: Syringe sharing was associated with HCV seroconversion [pooled risk ratio (PRR) = 1.94, 95% confidence interval (CI) 1.53, 2.46], as was sharing drug preparation containers (PRR = 2.42, 95% CI 1.89, 3.10), filters (PRR = 2.61, 95% CI 1.91, 3.56), rinse water (PRR = 1.98, 95% CI 1.54, 2.56), combinations of this equipment (PRR = 2.24, 95% CI 1.28, 3.93) and 'backloading', a syringe-mediated form of sharing prepared drugs (PRR = 1.86, 95% CI 1.41, 2.44). Meta-regression results showed that the association between syringe sharing and seroconversion was modified by HCV seroprevalence in the IDU populations.
CONCLUSIONS: The risk of hepatitis C infection through shared syringes is dependent upon hepatitis C infection seroprevalence in the population. The risk of hepatitis C infection through shared drug preparation equipment is similar to that of shared syringes. Because the infection status of sharing partners is often unknown, it is important for injection drug users to consistently avoid sharing unsterile equipment used to prepare, divide or inject drugs and avoid backloading with an unsterile syringe.
© 2011 The Authors, Addiction © 2011 Society for the Study of Addiction.

Entities:  

Mesh:

Year:  2012        PMID: 22168373      PMCID: PMC3348401          DOI: 10.1111/j.1360-0443.2011.03765.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  35 in total

1.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.

Authors:  J Zhang; K F Yu
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

2.  Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.

Authors:  N Crofts; C K Aitken
Journal:  Med J Aust       Date:  1997-07-07       Impact factor: 7.738

3.  Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.

Authors:  Lisa Maher; Bin Jalaludin; Kerry G Chant; Rohan Jayasuriya; Tim Sladden; John M Kaldor; Penny L Sargent
Journal:  Addiction       Date:  2006-10       Impact factor: 6.526

4.  High hepatitis C virus prevalence and incidence among Canadian intravenous drug users.

Authors:  E Roy; M Alary; C Morissette; P Leclerc; J-F Boudreau; R Parent; J Rochefort; C Claessens
Journal:  Int J STD AIDS       Date:  2007-01       Impact factor: 1.359

5.  Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

Authors:  S A Villano; D Vlahov; K E Nelson; C M Lyles; S Cohn; D L Thomas
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

6.  Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review.

Authors:  P De; E Roy; J-F Boivin; J Cox; C Morissette
Journal:  J Viral Hepat       Date:  2008-01-20       Impact factor: 3.728

7.  Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

Authors:  I van Beek; R Dwyer; G J Dore; K Luo; J M Kaldor
Journal:  BMJ       Date:  1998-08-15

8.  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.

Authors:  Charlotte H S B van den Berg; Colette Smit; Margreet Bakker; Ronald B Geskus; Ben Berkhout; Suzanne Jurriaans; Roel A Coutinho; Katja C Wolthers; Maria Prins
Journal:  Eur J Epidemiol       Date:  2007-03-03       Impact factor: 8.082

9.  A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users.

Authors:  Richard S Garfein; Elizabeth T Golub; Alan E Greenberg; Holly Hagan; Debra L Hanson; Sharon M Hudson; Farzana Kapadia; Mary H Latka; Lawrence J Ouellet; David W Purcell; Steffanie A Strathdee; Hanne Thiede
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

10.  Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.

Authors:  R S Garfein; M C Doherty; E R Monterroso; D L Thomas; K E Nelson; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998
View more
  59 in total

1.  Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City.

Authors:  Kelly Quinn; Chunki Fong; Honoria Guarino; Pedro Mateu-Gelabert
Journal:  Drug Alcohol Depend       Date:  2018-11-28       Impact factor: 4.492

2.  Hepatitis C virus serosorting in people who inject drugs: sorting out the details.

Authors:  Arthur Y Kim; Kimberly Page
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada.

Authors:  Samantha Young; Evan Wood; M-J Milloy; Kora DeBeck; Sabina Dobrer; Ekaterina Nosova; Thomas Kerr; Kanna Hayashi PhD
Journal:  Subst Abus       Date:  2018-10-02       Impact factor: 3.716

4.  Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.

Authors:  Enea Spada; Giovanni Rezza; Anna Rosa Garbuglia; Flavia Lucia Lombardo; Ornella Zuccaro; Francesca Menniti Ippolito; Elisabetta Cupellaro; Stefania Capone; Maria Rosaria Capobianchi; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Alfonso Mele
Journal:  J Urban Health       Date:  2018-02       Impact factor: 3.671

5.  Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania.

Authors:  Barrot H Lambdin; Jennifer Lorvick; Jessie K Mbwambo; John Rwegasha; Saria Hassan; Paula Lum; Alex H Kral
Journal:  Int J Drug Policy       Date:  2017-06-17

6.  More than just someone to inject drugs with: Injecting within primary injection partnerships.

Authors:  Meghan D Morris; Anna Bates; Erin Andrew; Judith Hahn; Kimberly Page; Lisa Maher
Journal:  Drug Alcohol Depend       Date:  2015-09-30       Impact factor: 4.492

7.  Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention.

Authors:  Kimberly Page; Meghan D Morris; Judith A Hahn; Lisa Maher; Maria Prins
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

8.  HCV infection status and care seeking among people living with HIV who use drugs in Vietnam.

Authors:  Li Li; Chunqing Lin; Li-Jung Liang; Quang Loc Pham; Nan Feng; Anh Tuan Nguyen
Journal:  AIDS Care       Date:  2020-05

9.  Pharmacokinetic interaction between telaprevir and methadone.

Authors:  Rolf van Heeswijk; Peter Verboven; Ann Vandevoorde; Petra Vinck; Jan Snoeys; Griet Boogaerts; Els De Paepe; Rodica Van Solingen-Ristea; James Witek; Varun Garg
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs.

Authors:  Lucy Platt; Jennifer Reed; Silvia Minozzi; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2016-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.